Abstract:Abstract Bispecific T cell engagers (BiTEs) that are specific for both a surface target antigen on cancer cells and CD3 on T cells have been used to engage T cells for cancer therapies. However, the development of BiTEs to treat cancer patients still faces enormous challenges. BiTEs need to penetrate well into tumor tissue, where the reactivate tumor resident T cells might have already been tolerized or energized by tumor microenvironments. In addition, the therapeutic potential of exogenously administered BiTEs could be limited by their short half-life and their dissociation from the triggering receptor within a relatively short period of time. RNA electroporation or lentiviral transduction of BiTEs into T cell could potentially enhance cancer treatment efficiency of both BiTEs and T cell adoptive immunotherapy of leukemia. In this study, we examined whether BiTEs could be produced by aCD3/aCD28 Dynal bead stimulated and expanded T cells that were electroporated with mRNA encoding BiTEs (Bis-RNA) and engage T cells specifically targeting tumors, both in vitro and in an aggressive leukemia animal model. We found that T cells with Bis-RNA encoding a CD19-CD3 BiTEs (Blinatumomab) could as efficiently recognize tumor as those T cells with CD19 CAR. We also discovered that the BiTEs secreted by Blinatumomab Bis-RNA transfected T cells could enable non-transfected T cells to specifically recognize CD19 positive tumors in vitro. Moreover, T cells with Bis-RNA showed increased sensitivity of tumor lysis and prolonged functional persistence, comparing to the CD19 CAR T cells. Upon specific antigen stimulation, T cells transfected with Bis-RNA secreted higher cytokines, showed more potent proliferation and less co-stimulation dependency, as well as more resistance to Treg and PD1 induced T cell suppression, than the T cells expressing CD19 CAR. In a Nalm6 leukemia mouse model, the anti-tumor activity of Blinatumomab Bis-RNA T cells showed more sustained anti-tumor activity comparing with CD19 RNA CAR T cells. A fully human CD19 RNA BiTE construct was successfully generated utilizing scFvs of both CD19 and CD3 fully human antibodies and the T cells transferred with this fully human CD19 BiTEs showed similar anti-tumor activities both in vitro and in Nalm6 leukemia model as Blinatumomab BiTEs. To maximize the dose of Bis-RNA electroporated T cells, we used the rapid T cell expansion protocol (REP) that uses OKT3 and IL-2 to stimulate T cells with irradiated allogeneic PBMCs as feeders. We found that this approach expands T cells up to 1000-fold in 10 days, which is 10 times more than aCD3/aCD28 Dynal bead stimulation. The T cells expanded by REP showed enhanced anti-tumor activities in vitro for both CD19 RNA CAR T or Bis-RNA T cells, as evidenced by increased CD137 up-regulation when the T cells were stimulated by CD19+ cell lines, and increased lytic ability, especially when the RNA input dose was limited. Moreover, CAR expression was higher for REP T cells than aCD3/aCD28 Dynal Beads T cells at different times after CAR RNA electroporation, indicating stronger and more persistent anti-tumor activities of REP T cells. To test if the improved anti-tumor activity of REP T cells evidenced in vitro correlates with their in vivo activity, T cells from the same normal donor were stimulated and expanded by either aCD3/aCD28 Dynal beads or REP and electroporated with CD19 CAR RNA or Blinatumomab Bis-RNA. The therapeutic results of those T cells in the NSG/Nalm6 model showed that better control of tumor growth was achieved by using REP CD19 CAR RNA T cells compared to CD19 CAR RNA T cells prepared by bead stimulation (P<0.01). Furthermore, using REP Bis-RNA T cells further improved the treatment results (P<0.05). It was found that treating NALM6 leukemia using REP Bis-RNA T cells led to significantly prolonged survival of the treated mice, which was comparable to what we have seen in the same mouse model treated with CD19 CAR lentivirally transduced T cells. In sumary, BiTEs could be efficiently produced and delivered by T cells to overcome the limitation of short half-life when using exogenously administered BiTEs. Introducing Bis-RNA into T cells for adoptive cell therapy, which not only takes the advantages of CAR based tumor antigen recognition that avoids most common tumor immune evasion mechanism, but also avoids the potential CAR based T cell activation defects, could be developed into a next generation adoptive immunotherapy. Disclosures Liu: University of Pennsylevania: Patents & Royalties: financial interests due to intellectual property and patents in the field of cell and gene therapy. Conflicts of interest are managed in accordance with University of Pennsylvania policy and oversight. Grupp:Novartis: Consultancy, Research Funding. June:Novartis: Research Funding; University of Pennsylvania: Patents & Royalties: financial interests due to intellectual property and patents in the field of cell and gene therapy. Conflicts of interest are managed in accordance with University of Pennsylvania policy and oversight. Zhao:Novartis: Patents & Royalties, Research Funding.

Sleeping Beauty Transposon‐mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies

Engineering of Α-Pd-1 Antibody-Expressing Long-Lived Plasma Cells by CRISPR/Cas9-mediated Targeted Gene Integration

Non-Viral Sleeping Beauty Transposon Engineered CD19-CAR-NK Cells Show a Safe Genomic Integration Profile and High Antileukemic Efficiency

The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies

Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System

Potent Anti-Leukemia Activities of Humanized CD19-targeted Chimeric Antigen Receptor T (CAR-T) Cells in Patients with Relapsed/refractory Acute Lymphoblastic Leukemia.

A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells

Improved Anti-Leukemia Activities of Adoptively Transferred T Cells Expressing Bites

Abstract B042: A bioengineered mammalian transposon for dual targeting CAR T cells: Addressing antigen escape in hematological cancers

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma

Abstract 2216: Combinational Strategy Targeting B Cell Malignancy Using Ipsc Engineered CAR-NK (FT596) and CAR-T Cell (FT819) Platforms with Therapeutic Antibody to Achieve an Effective Deep and Durable Response

Cord blood-derived CD19-specific chimeric antigen receptor T cells: an off-the-shelf promising therapeutic option for treatment of diffuse large B-cell lymphoma

Optimization of anti-CD19 CAR T-cell production for treatment of patients with chronic lymphocytic leukemia

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells

Development and clinical evaluation of non-viral genome specific targeted CAR T cells in relapsed/refractory B-cell non-Hodgkin lymphoma

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies